These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
150 related articles for article (PubMed ID: 7912166)
1. HER2/neu-derived peptides are shared antigens among human non-small cell lung cancer and ovarian cancer. Yoshino I; Goedegebuure PS; Peoples GE; Parikh AS; DiMaio JM; Lyerly HK; Gazdar AF; Eberlein TJ Cancer Res; 1994 Jul; 54(13):3387-90. PubMed ID: 7912166 [TBL] [Abstract][Full Text] [Related]
2. The HER2/neu-derived peptide p654-662 is a tumor-associated antigen in human pancreatic cancer recognized by cytotoxic T lymphocytes. Peiper M; Goedegebuure PS; Linehan DC; Ganguly E; Douville CC; Eberlein TJ Eur J Immunol; 1997 May; 27(5):1115-23. PubMed ID: 9174600 [TBL] [Abstract][Full Text] [Related]
3. TCR V beta 3+ and V beta 6+ CTL recognize tumor-associated antigens related to HER2/neu expression in HLA-A2+ ovarian cancers. Peoples GE; Yoshino I; Douville CC; Andrews JV; Goedegebuure PS; Eberlein TJ J Immunol; 1994 May; 152(10):4993-9. PubMed ID: 7909829 [TBL] [Abstract][Full Text] [Related]
4. Association of HER2/neu expression with sensitivity to tumor-specific CTL in human ovarian cancer. Yoshino I; Peoples GE; Goedegebuure PS; Maziarz R; Eberlein TJ J Immunol; 1994 Mar; 152(5):2393-400. PubMed ID: 8133050 [TBL] [Abstract][Full Text] [Related]
6. Pancreatic cancer associated ascites-derived CTL recognize a nine-amino-acid peptide GP2 derived from HER2/neu. Peiper M; Goedegebuure PS; Izbicki JR; Eberlein TJ Anticancer Res; 1999; 19(4A):2471-5. PubMed ID: 10470176 [TBL] [Abstract][Full Text] [Related]
7. Her-2/neu-derived peptides are tumor-associated antigens expressed by human renal cell and colon carcinoma lines and are recognized by in vitro induced specific cytotoxic T lymphocytes. Brossart P; Stuhler G; Flad T; Stevanovic S; Rammensee HG; Kanz L; Brugger W Cancer Res; 1998 Feb; 58(4):732-6. PubMed ID: 9485028 [TBL] [Abstract][Full Text] [Related]
8. Tumor-specific and HLA-A2-restricted cytolysis by tumor-associated lymphocytes in human metastatic breast cancer. Linehan DC; Goedegebuure PS; Peoples GE; Rogers SO; Eberlein TJ J Immunol; 1995 Nov; 155(9):4486-91. PubMed ID: 7594611 [TBL] [Abstract][Full Text] [Related]
9. Cytotoxic T cells isolated from ovarian malignant ascites recognize a peptide derived from the HER-2/neu proto-oncogene. Ioannides CG; Fisk B; Fan D; Biddison WE; Wharton JT; O'Brian CA Cell Immunol; 1993 Oct; 151(1):225-34. PubMed ID: 7691418 [TBL] [Abstract][Full Text] [Related]
10. Simultaneous production of T helper-1-like cytokines and cytolytic activity by tumor-specific T cells in ovarian and breast cancer. Goedegebuure PS; Douville CC; Doherty JM; Linehan DC; Lee KY; Ganguly EK; Eberlein TJ Cell Immunol; 1997 Feb; 175(2):150-6. PubMed ID: 9023420 [TBL] [Abstract][Full Text] [Related]
12. In vitro generation of human cytolytic T-cells specific for peptides derived from the HER-2/neu protooncogene protein. Disis ML; Smith JW; Murphy AE; Chen W; Cheever MA Cancer Res; 1994 Feb; 54(4):1071-6. PubMed ID: 7508819 [TBL] [Abstract][Full Text] [Related]
13. Oligopeptide induction of a cytotoxic T lymphocyte response to HER-2/neu proto-oncogene in vitro. Fisk B; Chesak B; Pollack MS; Wharton JT; Ioannides CG Cell Immunol; 1994 Sep; 157(2):415-27. PubMed ID: 7915203 [TBL] [Abstract][Full Text] [Related]
14. Comparison of various sources of antigen-presenting cells for the generation of GP2-tumor peptide specific cytotoxic T-lymphocytes. Peiper M; Goedegebuure PS; Alldinger I; Knoefel WT; Izbicki JR; Eberlein TJ Anticancer Res; 2002; 22(6A):3357-63. PubMed ID: 12530087 [TBL] [Abstract][Full Text] [Related]
15. Evaluation of the HER2/neu-derived peptide GP2 for use in a peptide-based breast cancer vaccine trial. Mittendorf EA; Storrer CE; Foley RJ; Harris K; Jama Y; Shriver CD; Ponniah S; Peoples GE Cancer; 2006 Jun; 106(11):2309-17. PubMed ID: 16596621 [TBL] [Abstract][Full Text] [Related]
16. HLA-A locus-restricted and tumor-specific CTLs in tumor-infiltrating lymphocytes of patients with non-small cell lung cancer. Seki N; Hoshino T; Kikuchi M; Hayashi A; Itoh K Cell Immunol; 1997 Feb; 175(2):101-10. PubMed ID: 9023415 [TBL] [Abstract][Full Text] [Related]
17. Small cell lung carcinomas express shared and private tumor antigens presented by HLA-A1 or HLA-A2. Yamazaki K; Spruill G; Rhoderick J; Spielman J; Savaraj N; Podack ER Cancer Res; 1999 Sep; 59(18):4642-50. PubMed ID: 10493519 [TBL] [Abstract][Full Text] [Related]
18. Identification of the HLA-Cw*0702-restricted tumor-associated antigen recognized by a CTL clone from a lung cancer patient. Nagata Y; Hanagiri T; Takenoyama M; Fukuyama T; Mizukami M; So T; Ichiki Y; Sugaya M; Sugio K; Yasumoto K Clin Cancer Res; 2005 Jul; 11(14):5265-72. PubMed ID: 16033845 [TBL] [Abstract][Full Text] [Related]
19. Two proliferation-related proteins, TYMS and PGK1, could be new cytotoxic T lymphocyte-directed tumor-associated antigens of HLA-A2+ colon cancer. Shichijo S; Azuma K; Komatsu N; Ito M; Maeda Y; Ishihara Y; Itoh K Clin Cancer Res; 2004 Sep; 10(17):5828-36. PubMed ID: 15355913 [TBL] [Abstract][Full Text] [Related]
20. Induction of human tumor-associated differentially expressed gene-12 (TADG-12/TMPRSS3)-specific cytotoxic T lymphocytes in human lymphocyte antigen-A2.1-positive healthy donors and patients with advanced ovarian cancer. Bellone S; Anfossi S; O'Brien TJ; Cannon MJ; Silasi DA; Azodi M; Schwartz PE; Rutherford TJ; Pecorelli S; Santin AD Cancer; 2009 Feb; 115(4):800-11. PubMed ID: 19117353 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]